1. Home
  2. TRVI vs DAVA Comparison

TRVI vs DAVA Comparison

Compare TRVI & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • DAVA
  • Stock Information
  • Founded
  • TRVI 2011
  • DAVA 2000
  • Country
  • TRVI United States
  • DAVA United Kingdom
  • Employees
  • TRVI N/A
  • DAVA N/A
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • DAVA EDP Services
  • Sector
  • TRVI Health Care
  • DAVA Technology
  • Exchange
  • TRVI Nasdaq
  • DAVA Nasdaq
  • Market Cap
  • TRVI 725.7M
  • DAVA 827.6M
  • IPO Year
  • TRVI 2019
  • DAVA 2018
  • Fundamental
  • Price
  • TRVI $6.55
  • DAVA $13.72
  • Analyst Decision
  • TRVI Strong Buy
  • DAVA Buy
  • Analyst Count
  • TRVI 9
  • DAVA 8
  • Target Price
  • TRVI $19.94
  • DAVA $26.75
  • AVG Volume (30 Days)
  • TRVI 1.6M
  • DAVA 819.7K
  • Earning Date
  • TRVI 08-07-2025
  • DAVA 05-14-2025
  • Dividend Yield
  • TRVI N/A
  • DAVA N/A
  • EPS Growth
  • TRVI N/A
  • DAVA N/A
  • EPS
  • TRVI N/A
  • DAVA 0.40
  • Revenue
  • TRVI N/A
  • DAVA $1,007,631,882.00
  • Revenue This Year
  • TRVI N/A
  • DAVA $6.33
  • Revenue Next Year
  • TRVI N/A
  • DAVA N/A
  • P/E Ratio
  • TRVI N/A
  • DAVA $34.49
  • Revenue Growth
  • TRVI N/A
  • DAVA 5.95
  • 52 Week Low
  • TRVI $2.36
  • DAVA $13.39
  • 52 Week High
  • TRVI $7.48
  • DAVA $34.94
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 61.06
  • DAVA 35.26
  • Support Level
  • TRVI $5.41
  • DAVA $14.69
  • Resistance Level
  • TRVI $6.08
  • DAVA $15.89
  • Average True Range (ATR)
  • TRVI 0.32
  • DAVA 0.65
  • MACD
  • TRVI 0.09
  • DAVA -0.04
  • Stochastic Oscillator
  • TRVI 96.20
  • DAVA 12.41

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

Share on Social Networks: